Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

• Status: Not yet recruiting
• Trial end date: 2026-02-06
• Target enrollment: 0
• Participant gender: All

Summary

Vonoprazan Amoxicillin and metronidazole based triple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the Vonoprazan, amoxicillin and metronidazole based triple therapy and the empiric bismuth quadruple therapy in the naive patients with Helicobacter pylori infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai East Hospital
• Treatments: Amoxicillin; Bismuth; Esomeprazole; Metronidazole; Potassium Citrate

Criteria

Inclusion Criteria:

• Participants with non-ulcer functional dyspepsia or peptic ulcer disease

• Ability and willingness to participate in the study and to sign and give informed consent

• Confirmed H. pylori infection and with no previous treatment experience

Exclusion Criteria:

• Less than 18 years old

• With previous gastric surgery

• Major systemic diseases

• Pregnancy or lactation

• Allergy to any of the study drugs Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion